Natera, Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This filing reports full-year results; it does not provide a clear standalone Q4 financial summary.
Business context
Natera develops molecular diagnostic tests using cell-free DNA and bioinformatics, principally in women’s health, with expanding oncology and organ-health offerings. Panorama prenatal screening and Horizon carrier screening generated the significant majority of revenue. The company also commercializes Signatera for cancer residual-disease monitoring, Prospera for kidney-transplant rejection assessment, and the Constellation laboratory licensing platform.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Total revenue | $391.0 million | $302.3 million |
| Product revenue | $367.2 million | $269.9 million |
| Licensing and other revenue | $23.8 million | $32.4 million |
| Gross profit, calculated as revenue less stated cost of revenue | $187.4 million; 47.9% margin | $126.9 million; 42.0% margin |
| Operating loss | $216.3 million | $116.3 million |
| Net loss | $229.7 million | $124.8 million |
| Net loss per share, basic and diluted | $2.84 | $1.79 |
| Cash used in operating activities | $182.5 million | $63.4 million |
| Cash, cash equivalents and restricted cash | $48.9 million | $62.0 million |
| Short-term investments | $688.6 million | $379.1 million |
| Total assets | $932.2 million | $582.7 million |
| Total liabilities | $445.9 million | $303.9 million |
Tests processed rose to approximately 1.03 million from 804,300, while reported test units increased to approximately 962,400 from 763,900. The company’s balance sheet showed $862.7 million of current assets and $199.1 million of current liabilities at year-end.
Debt included $287.5 million principal of 2.25% convertible senior notes due 2027 and approximately $49.0 million outstanding under a secured UBS credit line, including accrued interest. The notes’ year-end net carrying amount was $202.5 million due to accounting discounts. FY2020 financing included $270.7 million net proceeds from an equity offering and $278.3 million net proceeds from the notes; the company used proceeds to repay its OrbiMed term loan.
Material changes versus FY2019
- Revenue increased 29.3%, primarily reflecting growth in testing volumes and product revenue. Product revenue grew 36.1%; licensing and other revenue declined 26.7%, partly because Evercord had been sold in 2019.
- Net loss widened by $104.9 million. Research and development expense rose 94.8% to $100.0 million and selling, general and administrative expense rose 47.3% to $303.6 million, driven mainly by hiring, stock compensation, clinical studies, and legal and consulting costs.
- Operating cash use increased to $182.5 million from $63.4 million. The filing cites higher receivables, inventory and prepaid-asset balances among the working-capital uses.
- Stock-based compensation increased to $50.2 million from $28.6 million. FY2019 included a $14.4 million gain on the Evercord sale; FY2020 did not.
- FY2020 product volumes and average selling prices increased despite pandemic disruption. The filing does not quantify a standalone Q4 impact.
Outlook, risks and unusual items
- Management expected continued losses and negative operating cash flows in the near future. Based on its business plan, it believed cash and marketable securities would cover anticipated cash requirements for at least 12 months after February 25, 2021; additional financing could still be needed to support growth and commercialization.
- COVID-19 affected customer access, sales activity, operations and costs. Its future impact remained uncertain, although 2020 test volumes and average selling prices increased.
- Panorama and Horizon remain key revenue drivers. Reimbursement, especially for microdeletion screening and expanded carrier screening, is subject to payer decisions and coding-related rate pressure. Management noted broader average-risk NIPT coverage, while reimbursement for microdeletions remained low.
- Product development, clinical evidence and adoption of newer oncology and organ-health tests remain uncertain. The SMART study was expected to be published in 2021; its results could affect coverage and adoption of Panorama for average-risk pregnancies and microdeletions.
- Operational risks include dependence on Illumina sequencing instruments and reagents, Streck collection tubes, and a cloud platform without a backup platform. The filing also cites competition, regulatory uncertainty for laboratory-developed tests, and potential payer recoupments.
- The company disclosed multiple intellectual-property disputes, including claims involving CareDx, Ravgen, Progenity, ArcherDX/Invitae and others. The Illumina litigation was settled in May 2020. Management reported no recorded accrual for legal proceedings and said losses were not determined probable or reasonably estimable.
- The 2020 results included a $5.8 million loss on extinguishment of the OrbiMed term loan. The auditors issued an unqualified opinion on the financial statements and internal control over financial reporting.
Investor verification priorities
- Check subsequent revenue, gross-margin and cash-burn trends, including whether volume growth converts into improved operating leverage.
- Review cash and investment balances against operating cash use, the UBS credit-line terms, and the notes’ conversion, repayment and dilution implications.
- Verify payer coverage and realized reimbursement rates for Panorama, Horizon, Signatera and Prospera, including any refund or recoupment developments.
- Assess SMART study publication and findings, and clinical validation, reimbursement and adoption progress for oncology and organ-health products.
- Monitor litigation outcomes, supplier continuity and regulatory developments affecting laboratory-developed tests and international sales.